Radiotherapeutics

Our innovative approach

Radiotherapeutics represent a powerful clinical modality, particularly for the diagnosis and treatment of cancer. However, limitations and restrictions associated with the laboratory use of radioactivity can make their discovery and development uniquely challenging. At Momentum, we upgrade the traditional approach to radiotherapeutic development by coupling the use of a surrogate payload with the ultra-sensitive quantitative detection capabilities of ICP-MS. As a result, radioligand candidates can be identified and characterized safely, simply, and rapidly.

Avoid safety and regulatory concerns associated with radioactivity by harnessing a lanthanide or other surrogate payload
Straightforward sample prep is well-suited to cell culture, biofluids, and tissue/tumor samples
Multiplexing enables up to 14 ligands to be evaluated in a single experiment

How we can help

Non-Covalent Binding Assays
Affinity selection mass spectrometry (ASMS) is used to identify small molecule ligands against targets (including membrane proteins, protein complexes, and DNA/RNA). After validation and characterization, ligands identified by ASMS can be further developed into powerful radiotherapeutics.
ICP-MS
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) can be used to quantify surrogate lanthanides with parts-per-trillion sensitivity from complex matrices (cell pellets, tissues, biofluids). No chromatography is required, and throughput can be further increased by multiplexing.

Explore Other Modalities

We offer support for the development of a broad range of therapeutic modalities.

Molecular Glues
Induce or stabilize protein-protein interactions for therapeutic applications
Targeted Degraders
Induce target degradation with precision and potency
Covalent Drugs
Unlock potent and selective therapeutics through covalent binding
DNA- and RNA-Targeting Drugs
Accelerate the development of DNA- and RNA-targeted small-molecule therapeutics
Oligonucleotide Therapeutics
Modulate protein expression and splicing with RNA-binding ASOs and RNAi
Kinase Inhibitors
Develop selective and potent protein kinase inhibitors
ADCs
Targeted immunotherapeutics for cancer treatment and beyond
Gene Therapies
Modify genetic content and expression to enable new frontiers of disease treatment
Cell Therapies
Harness the power of cell therapy to overcome unmet disease challenges